Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray

Year 2017, Volume: 7 Issue: 2, 68 - 74, 30.09.2017

Aeksandar Perić Sandra Vezmar Kovačević Dejan Gaćeša Aneta Perić

Abstract

Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS.

Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 μg twice daily for 7 days. Group 2 (n=23) received only MFNS 200 μg twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p<0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.

Keywords

Glucocorticoids, inflammation, medicinal plants, rhinitis, sinusitis, Glukokortikoidler, inflamasyon, rinit, sinüzit, tıbbi bitki

References

• 1. Alobid I, Mullol J. Management of rhinosinusitis today. Clin Pulm Med 2008;15:332–41. 2. Mullol J. Trends on rhinosinusitis diagnosis and treatment. Otolaryngol Pol 2009;63:3–4. 3. Opoku-Buabeng J, Lartey SY. Obrital complications of sinusitis in children in Komfo Anokye Teaching Hospital. ENT Updates 2017;7:38–41. 4. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008;371(9616):908–14. 5. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusi- tis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116: 1289–95. 6. El-Hennawi DM, Ahmed MR, Farid AM, Al Murtadah AM. Comparative study of the efficacy of topical steroid and antibiotic combination therapy versus oral antibiotic alone when treating acute rhinosinusitis. J Laryngol Otol 2015;129:462–7. 7. Virgin F, Zhang S, Schuster D, et al. The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010;120:1051–6. 8. Kreindler JL, Chen B, Kreitman Y, Kofonow J, Adams KM, Cohen NA. The novel dry extract BNO 1011 stimulates chloride transport and ciliary beat frequency in human respiratory epithe- lial cultures. Am J Rhinol Allergy 2012;26:439–43. 9. Glatthaar-Saalmüller B, Rauchhaus U, Rode S, Haunschild J, Saalmüller A. Antiviral activity in vitro of two preperations of the herbal medicinal product Sinupret ® against viruses causing respi- ratory infections. Phytomedicine 2011;19:1–7. 10. Passali D, Loglisci M, Passali GC, Cassano P, Rodriguez HA, Bellussi LM. A prospective open-label study to assess the efficacy and safety of a herbal medicinal product (Sinupret) in patients with acute rhinosinusitis. ORL J Otorhinolaryngol Relat Spec 2015;77:27–32. 11. Jund R, Mondigler M, Steindl H, Stammer H, Stierna P, Bachert C; RhiSi II Study Group. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis. Rhinology 2012;50:417– 26. 12. Palm J, Steiner I, Abramov-Sommariva D, et al. Assessment of effi- cacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis. Rhinology 2017;55:142–51. 13. Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012;23:1–298. 14. Meltzer EO, Teper A, Danzig M. Intranasal corticosteroids in the treatment of acute rhinosinusitis. Curr Allergy Asthma Rep 2008; 8:133–8. 15. Rossi A, Dehm F, Kiesselbach C, Haunschild J, Sautebin L, Werz O. The novel Sinupret ® dry extract exhibits anti-inflam- matory effectiveness in vivo. Fitoterapia 2012;83:715–20. 16. Passali D, Cambi J, Passali FM, Bellussi LM. Phytoneering: a new way of therapy for rhinosinusitis. Acta Otorhinolaryngol Ital 2015;35:1–8. 17. Yaremchuk S, Zabolotny D, Vareniuk I, Makarchuk N, Veselsky S. Sinupret ® oral drops protect against respiratory epithelium atrophy in experimental acute rhinitis. Clinical Phytoscience 2015;1:8.